Summary
New Zealand cellular health brand MitoQ, exhibiting at the China International Import Expo for the ninth consecutive year, held a signing ceremony on 6 November 2026 at the ninth CIIE for the Asia debut of its MitoQ Cell Essentials range and a strategic healthy ageing partnership, marking its first appearance in the medical devices and healthcare exhibition area. Attendees included New Zealand Consul-General in Shanghai Ardi Barnard, MitoQ chief executive Mahara Inglis, MitoQ general manager for China and Asia-Pacific Li Zhouyi, Lecheng Administration industrial development director Kong Xiankai and Yiling Medical Technology Group chairman Li Wei. MitoQ Mitoquinol (mitoquinol mesylate) has received formal recognition from Australia's Therapeutic Goods Administration (TGA) and been added to Australia's list of permitted ingredients for listed complementary medicines.
MitoQ has posted double-digit growth in the China market for several consecutive years. The Asia debut of the Cell Essentials range introduced three new products: a marine fucoxanthin capsule, an equol women's balance capsule and a triple magnesium complex capsule. The range's first high-purity fish oil product had its global debut at the 2024 CIIE.
MitoQ has built a multi-tier product matrix spanning the MitoQ+ range, the MitoQ Pro professional range and the MitoQ Cell Essentials range. At the event, MitoQ signed a strategic healthy ageing cooperation agreement with Yiling Medical Technology Group, which has more than 20 years of experience in the broader health sector, to move from product placement to a closed-loop service model and tap China's longevity economy.
Commentary
MitoQ's ninth consecutive CIIE appearance and its first move into the medical devices and healthcare exhibition area signal an extension from dietary supplements into more professional health management. TGA recognition of its core ingredient Mitoquinol adds a compliance endorsement for its promotion in China. China's health consumer market is upgrading from basic nutrition to precision intervention, and MitoQ's multi-tier product matrix, from the mitochondria-targeted MitoQ+ range to the everyday-nutrition Cell Essentials range, fits that trend.
For New Zealand small and medium-sized enterprises, MitoQ's path shows a workable strategy for entering China's broader health market: build brand awareness through platforms such as the CIIE, then use local partnerships, such as the strategic tie-up with Yiling Medical Technology Group, to reach lower-tier channels and complete a service loop. Competition in China's health supplement market is intense, however, with local brands such as By-health and Swisse (now owned by Chinese capital) holding significant share, and regulation tightening, so NZ firms need sustained investment in scientific validation and differentiated positioning. The MitoQ-Yiling partnership focuses on healthy ageing, and with China's population aged 60 and over exceeding 300 million, the longevity economy has substantial potential, though how the cellular health concept can be turned into a replicable business model remains to be seen.
Keywords: MitoQ, China International Import Expo, Cell Essentials Asia debut, healthy ageing, Yiling Medical Technology Group, cellular health, TGA certification, strategic partnership, product matrix, China market
Image for illustration purposes
Source: Sina Finance
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.





